Published in final edited form as:

J Pediatr Gastroenterol Nutr. 2011 November ; 53(5): 569–574. doi:10.1097/MPG.0b013e3182267a66.

Vitamin D Deficiency is Prevalent in Females with Rett Syndrome

Kathleen J. Motil, M.D., Ph.D.^{1,2}, Judy O. Barrish, B.S.N., R.N.², Jane Lane, B.S.N., R.N.⁴, Suzanne P. Geerts, M.S., R.D.⁵, Fran Annese, L.M.S.W.⁷, Lauren McNair, M.S., C.G.C.⁷, Alan K. Percy, M.D.⁶, Steven A Skinner, M.D.⁷, Jeffrey L. Neul, M.D., Ph.D.^{2,3}, and Daniel G. Glaze, M.D.^{2,3}

¹USDA/ARS Children's Nutrition Research Center, Houston, TX 77030

²Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030

³Department of Neurology, Baylor College of Medicine, Houston, TX 77030

⁴Civitan International Research Center, University of Alabama at Birmingham, Birmingham, AL 35294

⁵Civitan-Sparks Clinics, University of Alabama at Birmingham, Birmingham, AL 35294

⁶Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL 35294

⁷Greenwood Genetics Center, Greenwood, SC 29646

Abstract

Objectives—To determine the prevalence of vitamin D deficiency and identify the relation between 25-hydroxyvitamin D [25(OH)D] levels and the consumption of dietary sources of vitamin D or exposure to anticonvulsants in females with Rett syndrome (RTT).

Study design—Retrospective review of the medical records of 284 females with RTT to determine serum 25(OH)D and parathyroid hormone levels, nutritional status, dietary sources of vitamin D, exposure to anticonvulsants, degree of mobility, and *MECP2* status.

Results—Twenty percent of females who were tested (n=157) had 25(OH)D levels <50 nmol/L. Multivitamin supplements, vitamin D fortified milk, and commercial formulas were consumed by 40%, 52%, and 54%. Anticonvulsants were used by 57% and 39% ambulated independently. Median 25(OH)D levels were lower in individuals who did not receive multivitamin supplements (p<0.05) or commercial formulas (p<0.001) than in those who did. Median 25(OH)D levels differed (p<0.01) among racial and ethnic groups, but the number in some groups was small. Nutritional status, use of anticonvulsants, degree of mobility, and *MECP2* status did not influence 25(OH)D levels.

Conclusion—Vitamin D deficiency is prevalent in females with RTT. The use of multivitamin supplements or commercial formulas is associated with improved vitamin D levels. Attention to vitamin D may enhance bone mineral deposition and reduce the frequency of bone fractures in these individuals.

Address correspondence to: Kathleen J. Motil, M.D., Ph.D., Children's Nutrition Research Center, 1100 Bates Street, Houston, TX 77030, TEL: (713) 798-7180, FAX: (713) 798-7109, kmotil@bcm.edu.

Financial disclosures: The authors report the following financial disclosures: Drs. Motil, Skinner, Percy, Neul, and Glaze, and Ms. Barrish, Lane, Geerts, Annese, and McNair receive research support from NIH (NCRR U54 RR019478, U54 HD061222).

Keywords

low bone mineral density; bone fracture; anticonvulsants; *MECP2* mutation; multivitamin supplements; milk products

Rett syndrome (RTT) is an X-linked neurodevelopmental disorder that occurs in 1.09/10,000 females.¹ Mutations in the gene encoding methyl-CpG-binding protein 2 (*MECP2*) can be identified in 90–95% of cases.^{2,3} The hallmark features of RTT are apparently normal development until 6 to 18 months of life, followed by a period of rapid developmental regression, loss of acquired speech, the replacement of purposeful hand use with hand stereotypies, and deceleration in head growth.^{4,5} Other features that may affect the clinical course of these individuals include growth abnormalities, seizures, autistic features, gait apraxia, and breathing abnormalities when awake.

As part of the growth abnormalities, girls and women with RTT have an increased risk of low bone mineral density, measured by dual-energy x-ray absorptiometry.^{6,7} The deficits in bone mineralization increase with advancing age.⁶ Deficits in lean body mass, the use of anticonvulsants, and poor ambulatory status may contribute to their bone mineral deficits.^{6,8} As a consequence, girls and women with RTT are at increased risk for skeletal fractures with advancing age.⁶ We estimate that 30% of these individuals have fractures by age 30 years based on national survey data (K.J. Motil, unpublished data).

Vitamin D is a prohormone essential for the absorption of calcium from the gut. Vitamin D deficiency has well-known adverse effects on bone health, including rickets in children and osteomalacia in adults.^{9,10} Vitamin D insufficiency in adults has been defined on the basis of parathyroid hormone (PTH) levels, calcium absorption, and bone mineral density.^{11–13} In adults, serum 25(OH)D levels ≥ 100 nmol/L also have been associated with maximal suppression of PTH and reduced fracture rates.¹⁴ In contrast, the true prevalence of vitamin D deficiency in children is unknown, in part, because of the absence of functional biomarkers such as PTH in this age group.¹⁵ Limited data in adolescents suggest that total Ca absorption in adolescents correlates with serum 25-hydroxyvitamin D [25(OH)D] levels in early, but not pre- or late puberty.¹⁶ Fractional calcium absorption adjusted for calcium intake is higher at lower vitamin D intakes when serum values are <50 nmol/L, presumably reflecting a compensatory response to increased PTH and 1,25-dihydroxyvitamin D levels.¹⁶ Preliminary data from our studies suggests that 25(OH)D may be associated with bone density in females with RTT.⁶

The 2011 Report on Dietary Reference Intakes from the Institute of Medicine (IOM) states that the recommended dietary allowance for vitamin D, 600 IU/day for ages 1–70 yr, corresponds to a serum 25-hydroxyvitamin D level of at least 50 nmol/L and meets the requirement of at least 97.5% of the population based on available scientific evidence relating vitamin D to bone health during conditions of minimal sun exposure.¹⁷ In the context of the IOM report, we designed this study to determine the prevalence of vitamin D deficiency in females with RTT and identify factors that favorably or adversely influence the vitamin D status of these individuals. We hypothesized that: 1) vitamin D deficiency is prevalent in girls and women with RTT, and 2) low 25(OH)D levels are associated with decreased consumption of dietary sources of vitamin D and increased exposure to anticonvulsant medications. We anticipate that attention to vitamin D nutrition in affected females may reduce the risk of bone fractures in these individuals.

Subjects and Methods

Subjects

Females who met the clinical diagnostic criteria for RTT with or without a *MECP2* mutation, ages 1 to 60 y, were eligible for study.^{4,5} All individuals were followed through The Blue Bird Circle Rett Center at Texas Children's Hospital, Houston, TX and/or the Rare Diseases Clinical Research Network (<http://www.clinicaltrials.gov>, Identifier NCT00296312) at one of four locations throughout the United States. Individuals whose medical or research records contained information about their dietary sources of vitamin D intake, the current use of anticonvulsant medications, and their degree of mobility were selected for study. The RTT cohort (n=284) was a sample of convenience based on the number of individuals followed by the investigators for clinical and research purposes between November 1, 2007, and December 31, 2009. Complete data sets for 25(OH)D and PTH concentrations were available for a variable number of subjects because of accessibility to individual medical or research records and the information provided by the primary care physicians.

The study was approved and a waiver of informed consent was granted by the Institutional Review Board for Human Subject Research at Baylor College of Medicine.

Study Design

The study design was observational. The medical and research records of a cohort of females with RTT were reviewed retrospectively to: 1) determine the prevalence of low serum 25(OH)D levels and 2) identify risk factors associated with altered vitamin D status.

Procedures

All nutritional and clinical assessments were documented in the medical or research records using a structured questionnaire. Three investigators (KJM, SPG, and FA) were responsible for the nutritional assessments and measurements; the remaining investigators were responsible for the clinical assessments. The following data were obtained from the medical or research records: demographic information, dietary sources of vitamin D, the current use of anticonvulsant medications, the degree of mobility, and laboratory values for 25(OH)D and PTH.

Demographic data—Demographic information included the individual's age, race or ethnicity, *MECP2* mutation, body mass index (BMI) z-score as a measure of nutritional status, and location of the clinical or research site. Race and ethnicity were categorized as: 1) Caucasian (non-Hispanic), 2) African-American, 3) Hispanic, 4) Asian, and 5) Native American. *MECP2* mutations were grouped into the following categories: early or late truncation (defined as truncating before amino acid 271 for early or after amino acid 271 for late), missense, large deletion, individually as one of eight common mutations (R106W, R133C, T158M, R168X, R255X, R270X, R294X, R306C), no mutation with expanded testing, or unknown. BMI was calculated from height and weight measurements and converted to gender- and age- appropriate z-scores.¹⁸ BMI z-scores were categorized as underweight (< -2 SD), normal weight ($\pm$ 2 SD), or overweight (> 2 SD) relative to the reference standards. The location of the clinical and research sites included: Houston, TX; Chicago, IL, Tampa/Miami, FL; New Brunswick, NJ; and Oakland, CA.

Nutritional data—Dietary sources of vitamin D included a categorical (yes/no) assessment of: 1) the daily use of multivitamin supplements containing vitamin D, 400 IU/dose, 2) the daily consumption of vitamin D-fortified milk, whether skim, 1%, 2%, whole milk, or soy, and 3) the daily consumption of a standard, vitamin D-fortified, commercially available,

pediatric or adult formula (e.g., Pediasure, Boost Kids Essentials, Vital Jr., Peptamen Jr.). The frequency of milk and formula consumption was assessed further as the number of 8-oz glasses of milk (vitamin D content ~100 IU/8 oz) or containers of formula (vitamin D content ~400 IU/8 oz) consumed daily. The categorical (yes/no) use of anticonvulsant medications was recorded, as well as the identification of specific drugs. The degree of mobility was used as a proxy for physical activity and was categorized as nonambulatory, ambulates independently, or ambulates with support. Scoliosis was recorded as present or absent.

Laboratory data—Clinical laboratory reports were reviewed for serum 25(OH)D and intact PTH values. Serum 25(OH)D and intact PTH levels were measured by standard clinical radioimmunoassay and electrochemiluminescent methods, respectively (Quest Laboratories Nichols Institute, San Juan Capistrano, CA; ARUP Laboratories, Salt Lake City, UT). The seasons of the year during which laboratory samples were obtained were categorized as summer (June, July, August), fall (September, October, November), winter (December, January, February), or spring (March, April, May). Vitamin D deficiency was defined as serum 25(OH)D concentrations <50 nmol/L.¹⁷ Vitamin D sufficiency was defined as serum 25(OH)D concentrations ≥ 50 nmol/L.

Statistical Analysis

Descriptive statistics (MiniTab, version 11.0, MiniTab, Inc., State College, PA) were expressed as mean ± SD if normally distributed or as median with 1st and 3rd interquartile ranges if non-normally distributed. Categorical variables were presented as frequency distributions. Nonparametric statistics using Kruskal-Wallis tests were applied to detect differences in 25(OH)D concentrations based on race or ethnicity, dietary intake of vitamin D food sources, nutritional (BMI) status, current use of anticonvulsants, degree of mobility, season of the year, site location, and *MECP2* status. Mann-Whitney tests were used to determine post hoc differences in 25(OH)D and groups of dietary sources of vitamin D and race or ethnicity factors. Regression analysis was used to determine relations between serum 25(OH)D and BMI or PTH concentrations. General linear modeling was used to determine the relation between serum 25(OH)D concentrations and race or ethnicity, dietary factors, nutritional status, current use of anticonvulsants, degree of mobility, season of year, and *MECP2* status combined after adjusting for age. Values were considered to be statistically significant if $P < 0.05$.

Results

Subject Characteristics

The characteristics of individuals with RTT (n=284) are shown in Table 1. The age range of the cohort was skewed towards younger individuals with a median (1st and 3rd interquartile) age of 9.0 (5.7, 16.1) years. The racial and ethnic distribution was primarily Caucasian non-Hispanic. The nutritional status of the cohort was predominantly normal weight-for-height based on BMI z-scores. *MECP2* status was determined in 99% of the cohort; *MECP2* mutations were found in 94% of those tested. Individuals with one of the eight common mutations comprised 60% of those tested.

Vitamin D Status and Related Measures

Serum 25(OH)D levels were documented in 55% (n=157) of the cohort. Serum 25(OH)D concentrations were < 75 nmol/L in 60% (n=95) and <50 nmol/L in 20% (n=32) of the group. The median (1st and 3rd interquartile) 25(OH)D concentration for the cohort was 70 (52, 82) nmol/L; one individual had a value in excess of 50 nmol/L by a factor of sevenfold because of excessive supplemental ingestion. Median 25(OH)D concentrations differed

between those individuals with levels above and below the cut-off value of 50 nmol/L (75 vs. 37 nmol/L, $P<0.001$). The majority (81%) of the 25(OH)D samples was obtained at the TX site; median 25(OH)D concentrations did not differ among locations because of the small sample sizes of the remaining sites (data not shown). Nearly two-thirds of the serum 25(OH)D samples were obtained in the fall (24% of cohort) and winter (40% of cohort) months; however, median 25(OH)D concentrations did not differ among the seasons of the year. The median (1st and 3rd interquartile) PTH concentration of the group ($n=74$) was 22 ng/L (14, 31). Serum 25(OH)D concentrations were not associated with age, BMI, or serum PTH concentrations (data not shown).

Dietary, Medication, and Ambulatory Variables

Dietary sources of vitamin D, including multivitamin supplements, vitamin D fortified milk, and commercial formulas, were consumed by 40%, 52%, and 54%, respectively, of the cohort. The number of glasses of milk and containers of commercial formulas consumed daily was 1.5 ± 0.9 and 3.0 ± 1.7 , respectively. Fifty percent of the cohort consumed daily one dietary source of vitamin D, 37% consumed two dietary sources, 7% consumed three dietary sources, and 6% consumed no dietary sources of vitamin D. Anticonvulsant medications were used daily by 57% of the cohort; within this group ($n=163$), 61% used one anticonvulsant, 31% used two anticonvulsants, and 8% used three or more anticonvulsants. The most commonly used anticonvulsants included sodium valproate (26%), zonisamide (24%), levetiracetam (23%), and lamotrigine (21%). Thirty-nine percent of the cohort ambulated independently, 36% was nonambulatory, and 25% ambulated with support. Scoliosis was present in 54% of the cohort.

Variables Associated with Serum 25(OH)D Levels

Dietary vitamin D sources and race or ethnicity factors that contributed to serum 25(OH)D concentrations are shown in Table 2. Median serum 25(OH)D concentrations were significantly lower in individuals who did not receive multivitamin supplements or commercial formulas than in those who did. When individuals were grouped on the basis of the number of dietary sources of vitamin D consumed daily, median serum 25(OH)D concentrations were significantly lower in the group with none versus those who consumed one, two, or three dietary sources of vitamin D. Median serum 25(OH)D concentrations did not differ significantly based on age, nutritional status as measured by BMI z-scores; consumption of vitamin D fortified milk; current use anticonvulsants; ambulatory status, presence of scoliosis; season of the year, clinic or research site location, or *MECP2* status (data not shown). Median serum 25(OH)D concentrations were significantly different among the racial and ethnic groups, but the number of individuals in some minority groups was small. Post hoc analyses demonstrated significant differences in median serum 25-hydroxyvitamin D levels between Caucasian and Hispanic, but not Caucasian and African-American, females.

When all variables including race and ethnicity; nutritional status; *MECP2* mutation; dietary consumption of multivitamins, milk, or formula; use of anticonvulsant medications; ambulatory status; presence of scoliosis; and season of the year for blood sampling, were combined and adjusted for age, only the consumption of multivitamin supplements predicted differences in serum 25(OH)D concentrations; values were higher in those females who consumed multivitamin supplements compared with those who did not (83 ± 60 vs. 62 ± 52 nmol/L, $P<0.01$).

Discussion

Low bone mineral density and increased risk of bone fractures characterize the natural history of bone health in RTT.⁶ Our study demonstrated that vitamin D deficiency, i.e., 25(OH)D levels <50 nmol/L, was present in 20% of affected females who were tested. The use of vitamin supplements or vitamin D fortified formula favorably influenced serum 25(OH)D concentrations, whereas the use of anticonvulsants did not adversely affect their vitamin D status. We speculate that attention to vitamin D nutriture may favor enhanced bone mineral density and reduce the frequency of bone fractures in females with RTT.¹⁴

Evidence from single-center studies suggests that vitamin D deficiency occurs in healthy children of all ages.^{19–21} In a nationally representative sample of US children, ages 1–11 years, 15% had values <50 nmol/L.²² Among healthy adolescents, 42% were vitamin D deficient (<50 nmol/L).¹⁹ Low serum vitamin D levels are found in children with a variety of chronic diseases.^{23–27} Twenty-one percent of children with metabolic bone disease associated with chronic diseases had vitamin D levels <50 nmol/L.²³ The prevalence of vitamin D deficiency in the RTT cohort approximated values found in unaffected healthy children as well as some, but not all, individuals with other chronic disorders. Although our study did not include a control group, our data support the observation that vitamin D deficiency is not unique to RTT. Thus, early screening for vitamin D deficiency may be an important component of the health care of females with RTT. The somewhat lower prevalence may be related to the findings that the majority of the RTT cohort was well nourished by BMI criteria and 40% received a supplement that reliably provided adequate dietary intakes of vitamin D.

The cut-off value for vitamin D deficiency in children is controversial because available evidence is not sufficient to support the use of bone mineral content or PTH concentrations as functional outcomes in these individuals.^{11,21} Several groups have defined vitamin D deficiency in children as a serum 25(OH)D level <37.5 nmol/L and vitamin D sufficiency as >50 nmol/L.^{9,21} In adults, vitamin D deficiency, insufficiency, and sufficiency have been defined as 25-hydroxyvitamin D levels <45 nmol/L, 45 to <75 nmol/L, and ≥75 nmol/L, respectively, based on all-cause mortality and functional biomarkers including the serum PTH response to serum 25-hydroxyvitamin D levels, calcium absorption (balance) studies, and bone mineral content, measured by dual energy absorptiometry.^{28–32} In addition, serum 25(OH)D levels ≥100 nmol/L are associated with maximal suppression of PTH and reduced fracture rates in adults.¹⁴ If we used these higher cut-off values, the prevalence of vitamin D deficiency and insufficiency in the RTT cohort would have been 15% and 45%, respectively. In children, serum 25(OH)D concentrations may be inversely associated with serum PTH concentrations, but the correlation is poor.^{19,21,26} We did not observe a relation between serum 25(OH)D and PTH concentrations in our RTT cohort; however, only 26% had serum PTH levels measured.

Although many factors contribute to vitamin D deficiency, our study was not designed, nor powdered, to address the significance of risk factors on serum vitamin D status. A higher prevalence of vitamin D deficiency has been identified in older than in younger children.^{20,22} Low serum 25(OH)D levels may be inversely associated with body fatness.^{19,20,33} In the present study, we did not show age- or BMI-related differences in serum 25(OH)D concentrations in the RTT cohort. Decreased vitamin D synthesis in healthy children may be associated with decreased sunlight exposure because of inherently dark skin, the use of sunscreen, an indoor lifestyle, the latitude of living, or the season of the year.^{19–22,24,26,33} Of all these factors, only race and ethnicity influenced 25(OH)D levels in the RTT cohort. An increased prevalence of low 25(OH)D concentrations has been reported in healthy African-American and Hispanic adolescents, compared with healthy Caucasian

individuals in some, but not all, studies.^{19–23,33,34} We also found lower 25(OH)D concentrations in Hispanic, but not African-American, females with RTT, but our study was limited by insufficient number of individuals in some of the racial and ethnic groups to achieve statistical power to detect significance. We used degree of mobility as a surrogate marker of physical activity, and hence, exposure to sunlight. However, the ambulatory status of females with RTT did not show an association with 25(OH)D concentrations. Anecdotal reports from parents suggest that most females with RTT have limited outdoor sunlight exposure. Furthermore, children in southern latitudes are less likely to be outside during the intense summer heat. These observations may explain in part the lack of seasonal and site variation of 25(OH)D levels in the RTT cohort, although our study was not powered to detect differences among the groups. Finally, genetic factors may influence serum 25(OH)D levels. Differences in vitamin D binding protein genotypes, particularly T436K, may explain in part the variability of serum 25(OH)D levels among groups of individuals.³⁵ We did not characterize vitamin D binding protein in the present study.

Decreased dietary intake of vitamin D fortified foods, beverages, or supplements may contribute to vitamin D deficiency.^{12,19–22,24} Our data demonstrated that females with RTT who did not consume vitamin D fortified milk, formula, or supplements had quantitatively lower 25(OH)D concentrations than those who consumed one or more dietary sources of vitamin D. Vitamin supplements and formula consumption provided the strongest association with serum 25(OH)D concentrations because they contributed on average 400 and 300 IU, respectively, of dietary vitamin D daily. Limited milk consumption, i.e., an average of 1.5 glasses daily, failed to influence serum vitamin D levels in the RTT cohort because this amount provided only 150 IU of dietary vitamin D daily. When all factors were combined, the use of multivitamin supplements best predicted favorable 25(OH)D concentrations. In children with inflammatory bowel disease, 25(OH)D concentrations were 31% higher in those who received a multivitamin supplement than those who did not;²⁴ in the RTT cohort, 25(OH)D concentrations were only 15% higher in those females who received a multivitamin supplement. In one report, only 6% of healthy children who received a multivitamin supplement containing 400 IU of vitamin D had serum 25(OH)D concentrations <50 nmol/L.²² Our data showed that 22% of individuals who received a multivitamin supplement and were tested for their vitamin status had 25(OH)D values <50 nmol/L. These observations suggest that dietary vitamin D requirements for females with RTT may be higher than 400 IU/day, assuming that parents were consistent in the administration of the multivitamin supplement.

The use of medications such as anticonvulsants is associated with vitamin D deficiency.³⁶ A variety of older anticonvulsants that induce the hepatic CYP₄₅₀ enzyme system, including phenobarbital, phenytoin, and carbamazepine, has been implicated.³⁷ However, newer anticonvulsants may equally affect the vitamin D status of individuals with seizure disorders.³⁸ A direct effect of the drugs on bone cells has been proposed; however, the effect of the newer-generation antiepileptic medications on bone metabolism is unknown. Although more than 50% of the RTT cohort received anticonvulsants, we did not find an association between their use and 25(OH)D concentrations, but we did not determine whether the dose or duration of use differed among individuals. We observed that 85% of the RTT cohort received the newer anticonvulsants.

The prevention and treatment of vitamin D deficiency can be accomplished by greater exposure to sunlight in the absence of sunscreen for adequate vitamin D synthesis and the consumption of vitamin D fortified beverages or use of multivitamin supplements. Exposure of 20% of the unclothed body surface to the midday sun for 10–15 min in spring, summer, and fall is considered adequate for light-skinned people, providing approximately 25% of the amount of ultraviolet light required to produce slight pinkness of the skin.³⁹ Dark-

skinned individuals require 6 to 10 times as much ultraviolet light exposure as light-skinned individuals to achieve equivalent vitamin D concentrations.⁹ Children who do not ingest daily 1 L of vitamin D fortified milk should receive a supplement of at least 400 units/day with additional considerations for skin color and latitude of living.¹⁰ Children with increased risk for vitamin D deficiency may require higher doses of vitamin D supplementation to achieve serum 25(OH)D levels ≥ 50 nmol/L. Variability in vitamin D binding protein genotypes also may predict serum 25(OH)D responses to supplementation.³⁵ Because of the increased risk of low bone mineral density and fractures in girls and women with RTT,⁶ we routinely assess dietary vitamin D intakes, query the amount of sunlight exposure, determine serum 25(OH)D concentrations, and implement oral therapy if necessary. The long term benefit of this practice on bone health remains to be determined.

In summary, vitamin D deficiency is prevalent in females with RTT. The use of multivitamin supplements or commercial formulas is associated with improved vitamin D status in these individuals. Attention to vitamin D nutriture may improve bone health in this disorder.

Acknowledgments

Funding for this project was provided by the National Institutes of Health (NICHD U54 HD061222, NCRR U54 RR019478, and the Office of Rare Diseases Research), The Blue Bird Circle, and the Rett Syndrome Association of Illinois. The views expressed in written materials or publications do not necessarily reflect the official policies of the Department of Health and Human Services, nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

This work is a publication of the USDA/ARS Children's Nutrition Research Center, Baylor College of Medicine, Houston, TX, and has been funded in part with federal funds from the US Department of Agriculture, Agricultural Research Service (Cooperative Agreement Number 58-6250-1-003). The content of this publication does not necessarily reflect the views or policies of the US Department of Agriculture, nor does mention of trade names, commercial products, or organizations imply endorsement by this agency.

The authors thank J. Kennard Fraley for providing z-score values and E. O'Brien Smith, Ph.D., for statistical consultation and Mary Lou Oster-Granite, Ph.D. (NICHD) for her support and guidance. The authors acknowledge the cooperation and support of the families of our patients for whom we provide consultation and care.

Abbreviations

RTT	Rett syndrome
25(OH)D	25-hydroxyvitamin D
PTH	parathyroid hormone
MECP2	methyl-CpG-binding protein 2
BMI	body mass index
IOM	Institute of Medicine

References

1. Laurvick CL, deKlerk N, Bower C, Christodoulou J, Ravine D, Ellaway C, Williamson S, Leonard H. Rett syndrome in Australia: a review of the epidemiology. *J Pediatr*. 2006; 148:347–52. [PubMed: 16615965]
2. Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. *Nat Genet*. 1999; 23:185–8. [PubMed: 10508514]

3. Neul JL, Fang P, Barrish J, Lane J, Caeg EB, Smith EO, Zoghbi H, Percy A, Glaze DG. Specific mutations in *Methyl-CpG-Binding Protein 2* confer different severity in Rett syndrome. *Neurology*. 2008; 70:1313–21. [PubMed: 18337588]
4. Neul JL, Kaufmann WE, Glaze DG, Christodoulou J, Clarke AJ, Bahi-Buisson N, Leonard H, Bailey ME, Schanen NC, Zappella M, Renieri A, Huppke P, Percy AK. RettSearch Consortium. Rett syndrome: revised diagnostic criteria and nomenclature. *Ann Neurol*. 2010; 68:944–50. [PubMed: 21154482]
5. Hagberg B, Hanefeld F, Percy A, Skjeldal O. An update on clinically applicable diagnostic criteria in Rett syndrome. Comments to Rett Syndrome clinical criteria consensus panel satellite to European Paediatric Neurology Society meeting, Baden Baden, Germany, 11 September 2001. *Eur J Paediatr Neurol*. 2002; 6:293–7. [PubMed: 12378695]
6. Motil KJ, Ellis KJ, Barrish JO, Caeg E, Glaze DG. Bone mineral content and bone mineral density are lower in older than in younger females with Rett syndrome. *Pediatr Res*. 2008; 64:435–9. [PubMed: 18535484]
7. Motil KJ, Schultz RJ, Abrams S, Ellis KJ, Glaze DG. Fractional calcium absorption is increased in girls with Rett syndrome. *J Pediatr Gastroenterol Nutr*. 2006; 42:419–26. [PubMed: 16641581]
8. Leonard H, Thomson MR, Glasson EJ, Fyfe S, Leonard S, Bower C, Christodoulou J, Ellaway C. A population-based approach to the investigation of osteopenia in Rett syndrome. *Dev Med Child Neurol*. 1999; 41:323–8. [PubMed: 10378758]
9. Misra M, Pacaud D, Petryk A, Collett-Solberg PF, Kappy M. on behalf of the Drug and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society. Vitamin D deficiency in children and its management: review of current knowledge and recommendations. *Pediatrics*. 2008; 122:398–417. [PubMed: 18676559]
10. Wagner CL, Greer FR. the Section on Breastfeeding and Committee on Nutrition. Prevention of rickets and vitamin D deficiency in infants, children, and adolescents. *Pediatrics*. 2008; 122:1142–52. [PubMed: 18977996]
11. Vieth R, Ladak Y, Walfish PG. Age-related changes in the 25-hydroxyvitamin D versus parathyroid hormone relationship suggest a different reason why older adults require more vitamin D. *J Clin Endocrinol Metab*. 2003; 88:185–91. [PubMed: 12519850]
12. Heaney RP, Dowell MS, Hale CA, Bendich A. Calcium absorption varies within the reference range for serum 25-hydroxyvitamin D. *J Am Coll Nutr*. 2003; 22:142–6. [PubMed: 12672710]
13. Bischoff-Ferrari HA, Dietrich T, Orav E, Dawson-Hughes B. Positive association between 25-hydroxy vitamin D levels and bone mineral density: a population based study of younger and older adults. *Am J Med*. 2004; 116:634–9. [PubMed: 15093761]
14. Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson-Hughes B. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized control trials. *JAMA*. 2005; 293:2257–64. [PubMed: 15886381]
15. Greer FR. 25-Hydroxyvitamin D: functional outcomes in infants and young children. *Am J Clin Nutr*. 2008; 88(suppl):529S–33S. [PubMed: 18689395]
16. Abrams SA, Hicks PD, Hawthorne KM. Higher serum 25-hydroxyvitamin D levels in school-age children are inconsistently associated with increased calcium absorption. *J Clin Endocrinol Metab*. 2009; 94:2421–7. [PubMed: 19383779]
17. Committee to Review Dietary Reference Intakes for Vitamin D and Calcium, Food and Nutrition Board, Institute of Medicine. Dietary Reference Intakes for Vitamin D and Calcium. Washington, DC: The National Academy Press; 2010. p. 1-999. Accessed at: <http://www.iom.edu/Reports/2010/Dietary-Reference-Intakes-for-Calcium-and-Vitamin-D.aspx>
18. Centers for Disease Control and Prevention, National Center for Health Statistics. [Accessed June 28, 2010.] CDC growth charts: United States. <http://www.cdc.gov/growthcharts/>
19. Gordon CM, DePeters KC, Feldman HA, Grace E, Emans SJ. Prevalence of vitamin D deficiency among healthy adolescents. *Arch Pediatr Adolesc Med*. 2004; 158:531–7. [PubMed: 15184215]
20. Weng FL, Shults J, Leonard MB, Stallings VA, Zemel BS. Risk factors for low serum 25-hydroxyvitamin D concentrations in otherwise healthy children and adolescents. *Am J Clin Nutr*. 2007; 86:150–8. [PubMed: 17616775]

21. Rovner AJ, O'Brien KO. Hypovitaminosis D among healthy children in the United States. *Arch Pediatr Adolesc Med.* 2008; 162:513–9. [PubMed: 18524740]
22. Mansbach JM, Ginde AA, Camargo CA Jr. Serum 25-hydroxyvitamin D levels among US children aged 1 to 11 years: do children need more vitamin D? *Pediatrics.* 2009; 124:1404–10. [PubMed: 19951983]
23. Bowden SA, Robinson RF, Carr R, Mahan JD. Prevalence of vitamin D deficiency and insufficiency in children with osteopenia or osteoporosis referred to a pediatric metabolic bone clinic. *Pediatrics.* 2008; 121:e1585–90. [PubMed: 18519464]
24. Pappa HM, Gordon CM, Saslowsky TM, Zhouldev A, Horr B, Shih M-C, Grand RJ. Vitamin D status in children and young adults with inflammatory bowel disease. *Pediatrics.* 2006; 118:e1950–61.
25. Stephensen CB, Marquis GS, Kruzich LA, Douglas SD, Aldrovandi GM, Wilson CM. Vitamin D status in adolescents and young adults with HIV infection. *Am J Clin Nutr.* 2006; 83:1135–41. [PubMed: 16685057]
26. Rovner AJ, Stallings VA, Schall JJ, Leonard MB, Zemel BS. Vitamin D insufficiency in children adolescents, and young adults with cystic fibrosis despite routine oral supplementation. *Am J Clin Nutr.* 2007; 86:1694–9. [PubMed: 18065588]
27. Levin AD, Wadhera V, Leach ST, Woodhead HJ, Lemberg DA, Mendoza-Cruz AC, Day AS. Vitamin D deficiency in children with inflammatory bowel disease. *Dig Dis Sci.* 2011; 56:830–6. [PubMed: 21222159]
28. Melamed ML, Michol ED, Post W, Astor B. 25-Hydroxyvitamin D levels and the risk of mortality in the general population. *Arch Intern Med.* 2008; 168:1629–1637. [PubMed: 18695076]
29. Bischoff-Ferrari HA, Giovannucci E, Willett WC, Dietrich T, Dawson-Hughes B. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. *Am J Clin Nutr.* 2006; 84:18–28. [PubMed: 16825677]
30. Vieth R, Ladak Y, Walfish PG. Age-related changes in the 25-hydroxyvitamin D versus parathyroid hormone relationship suggest a different reason why older adults require more vitamin D. *J Clin Endocrinol Metab.* 2003; 88:185–191. [PubMed: 12519850]
31. Heaney RP, Dowell MS, Hale CA, Bendich A. Calcium absorption varies within the reference range for serum 25-hydroxyvitamin D. *J Am Coll Nutr.* 2003; 22:142–146. [PubMed: 12672710]
32. Bischoff-Ferrari HA, Dietrich T, Orav E, Dawson-Hughes B. Positive associations between 25-hydroxyvitamin D levels and bone mineral density: a population based study of younger and older adults. *Am J Med.* 2004; 116:634–639. [PubMed: 15093761]
33. Dong Y, Pollock N, Stallmann-Jorgensen IS, Gutin B, Lan L, Chen TC, Keeton D, Petty K, Holick MF, Zhu H. Low 25-hydroxyvitamin D levels in adolescents: race, season, adiposity, physical activity, and fitness. *Pediatrics.* 2010; 125:1104–11. [PubMed: 20439594]
34. Looker AC, Dawson-Hughes B, Calvo MS, Gunter EW, Sahyoun NR. Serum 25-hydroxyvitamin D status of adolescents and adults in two seasonal subpopulations from NHANES III. *Bone.* 2002; 30:771–7. [PubMed: 11996918]
35. Fu L, Yun F, Oczak M, Wong BYL, Vieth R, Cole DEC. Common genetic variants of the vitamin D binding protein (DBP) predict differences in response of serum 25-hydroxyvitamin D [25(OH)D] to vitamin D supplementation. *Clin Biochem.* 2009; 42:1174–7. [PubMed: 19302999]
36. Nettekoven S, Strohle A, Trunz B, Wolters M, Hoffmann S, Horn R, Steinert M, Brabant G, Lichtinghagen R, Welkoborsky H-J, Tuxhorn I, Hahn A. Effects of antiepileptic drug therapy on vitamin D status and biochemical markers of bone turnover in children with epilepsy. *Eur J Pediatr.* 2008; 167:1369–77. [PubMed: 18270736]
37. Samaniego EA, Sheth RD. Bone consequences of epilepsy and antiepileptic medications. *Semin Pediatr Neurol.* 2007; 14:196–200. [PubMed: 18070676]
38. Mintzer S, Boppana P, Toguri J, DeSantis A. Vitamin D levels and bone turnover in epilepsy patients taking carbamazepine or oxcarbazepine. *Epilepsia.* 2006; 47:510–5. [PubMed: 16529614]
39. Farrerons J, Barnadas M, Rodriguez J, Renau A, Yoldi B, Lopez-Navidad A, Moragas J. Clinically prescribed sunscreen (sun protection factor 15) does not decrease serum vitamin D concentration sufficiently either to induce changes in parathyroid function or in metabolic markers. *Br J Dermatol.* 1998; 139:422–7. [PubMed: 9767286]

Table 1

Characteristics of females (n = 284) with Rett syndrome

Characteristic	Number of Subjects	Value ^a
Age (y)	284	11.7 ± 8.4
Race/Ethnicity	284	
Caucasian (% of cohort)		69
African-American (% of cohort)		5
Hispanic (% of cohort)		19
Asian/Pacific Islander (% of cohort)		5
Native American (% of cohort)		2
Body mass index (z-score)	284	- 0.4 ± 1.7
Nutritional status ^b	284	
Underweight (BMI z-score < -2) (% of cohort)		15
Normal weight (BMI z-score -2 to +2) (% of cohort)		81
Overweight (BMI z-score > +2) (% of cohort)		4
MECP2 mutation	284	
Missense (% of cohort)		29
Early truncation (% of cohort)		35
Late truncation (% of cohort)		15
Large deletion (% of cohort)		12
Negative with expanded testing (% of cohort)		6
Unknown (% of cohort)		3

^aValues expressed % of cohort for group variables and as mean ± SD for continuous variables^bNutritional status expressed as body mass index, BMI

Table 2

Dietary sources of vitamin D and race or ethnicity factors that contribute to serum 25-hydroxyvitamin D concentrations in females with Rett syndrome (n = 157)

Variable	Number of Subjects	Median 25(OH)D ^a (nmol/L)	P-value
Multivitamin use			
No	103	65	<0.05
Yes	54	75	
Milk consumption			
No	81	72	NS
Yes	67	65	
Commercial formula use			
No	62	60	<0.001
Yes	95	72	
Number of dietary source of vitamin D consumed daily			
None	13	45	--- ^b
One	82	70	<0.001
Two	52	66	<0.001
Three	10	76	<0.001
Race and ethnicity			
Caucasian	99	72	--- ^b
African-American	10	54	NS
Hispanic	40	59	<0.001
Asian	4	57	---
Native American	4	79	---

^a25(OH)D, 25-hydroxyvitamin D

^bPost hoc Mann-Whitney tests for none vs. one, two, or three dietary sources of vitamin D and Caucasian vs. African-American or Hispanic groups; Asian and Native American groups not tested because of small sample size